

Peter Humaidan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/901808/publications.pdf>

Version: 2024-02-01

258
papers

12,103
citations

24978

57
h-index

34900

98
g-index

266
all docs

266
docs citations

266
times ranked

5705
citing authors

#	ARTICLE	IF	CITATIONS
1	Sperm DNA integrity assessment in prediction of assisted reproduction technology outcome. Human Reproduction, 2007, 22, 174-179.	0.4	639
2	GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction, 2005, 20, 1213-1220.	0.4	446
3	The predictive value of sperm chromatin structure assay (SCSA) parameters for the outcome of intrauterine insemination, IVF and ICSI. Human Reproduction, 2004, 19, 1401-1408.	0.4	413
4	A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertility and Sterility, 2016, 105, 1452-1453.	0.5	401
5	Fresh versus elective frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of reproductive outcomes. Human Reproduction Update, 2019, 25, 2-14.	5.2	307
6	GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Human Reproduction Update, 2011, 17, 510-524.	5.2	289
7	Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertility and Sterility, 2010, 94, 389-400.	0.5	276
8	1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertility and Sterility, 2010, 93, 847-854.	0.5	252
9	86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. Journal of Assisted Reproduction and Genetics, 2017, 34, 325-336.	1.2	230
10	ESHRE guideline: ovarian stimulation for IVF/ICSI. Human Reproduction Open, 2020, 2020, hoaa009.	2.3	205
11	The novel POSEIDON stratification of "Low prognosis patients in Assisted Reproductive Technology" and its proposed marker of successful outcome. F1000Research, 2016, 5, 2911.	0.8	201
12	GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reproduction, 2013, 28, 2511-2521.	0.4	197
13	LH-Receptor Gene Expression in Human Granulosa and Cumulus Cells from Antral and Preovulatory Follicles. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1524-E1531.	1.8	178
14	Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online, 2006, 13, 173-178.	1.1	173
15	Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. Fertility and Sterility, 2014, 101, 1008-1011.	0.5	159
16	Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Human Reproduction, 2016, 31, 795-803.	0.4	159
17	Intracytoplasmic sperm injection for male infertility and consequences for offspring. Nature Reviews Urology, 2018, 15, 535-562.	1.9	158
18	Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive BioMedicine Online, 2004, 8, 635-643.	1.1	145

#	ARTICLE	IF	CITATIONS
19	Biological versus chronological ovarian age: implications for assisted reproductive technology. <i>Reproductive Biology and Endocrinology</i> , 2009, 7, 101.	1.4	122
20	Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteriaâ€”The Why. <i>Frontiers in Endocrinology</i> , 2018, 9, 461.	1.5	122
21	Sperm DNA fragmentation testing: Summary evidence and clinical practice recommendations. <i>Andrologia</i> , 2021, 53, e13874.	1.0	121
22	Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. <i>Human Reproduction</i> , 2008, 24, 764-774.	0.4	119
23	Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials. <i>Human Reproduction</i> , 2016, 31, 1997-2004.	0.4	118
24	Elevated progesterone during ovarian stimulation for IVF. <i>Reproductive BioMedicine Online</i> , 2012, 24, 381-388.	1.1	115
25	Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. <i>Reproductive BioMedicine Online</i> , 2009, 18, 630-634.	1.1	112
26	Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. <i>Human Reproduction</i> , 2002, 17, 2016-2021.	0.4	107
27	Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. <i>Fertility and Sterility</i> , 2018, 109, 644-664.	0.5	105
28	Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. <i>Fertility and Sterility</i> , 2007, 88, 616-621.	0.5	101
29	Sperm chromatin structure assay parameters measured after density gradient centrifugation are not predictive for the outcome of ART. <i>Human Reproduction</i> , 2007, 23, 4-10.	0.4	94
30	Pregnancy loss after frozen-embryo transferâ€”a comparison of three protocols. <i>Fertility and Sterility</i> , 2012, 98, 1165-1169.	0.5	93
31	GnRHa to trigger final oocyte maturation: a time to reconsider. <i>Human Reproduction</i> , 2009, 24, 2389-2394.	0.4	92
32	Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. <i>Human Reproduction</i> , 2013, 28, 2529-2536.	0.4	92
33	The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. <i>Reproductive BioMedicine Online</i> , 2012, 24, 134-141.	1.1	89
34	GnRH agonist triggering: recent developments. <i>Reproductive BioMedicine Online</i> , 2013, 26, 226-230.	1.1	86
35	GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. <i>Reproductive BioMedicine Online</i> , 2016, 32, 274-285.	1.1	86
36	Perinatal outcomes after fresh versus vitrified-warmed blastocyst transfer: retrospective analysis. <i>Fertility and Sterility</i> , 2015, 104, 899-907.e3.	0.5	84

#	ARTICLE	IF	CITATIONS
37	Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. <i>Reproductive BioMedicine Online</i> , 2011, 23, 187-195.	1.1	83
38	Fertility after uterine artery embolization of fibroids: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 13-25.	0.8	83
39	Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. <i>Human Reproduction Update</i> , 2018, 24, 599-614.	5.2	83
40	COVID-19 and assisted reproductive technology services: repercussions for patients and proposal for individualized clinical management. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 45.	1.4	81
41	GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. <i>Human Reproduction</i> , 2012, 27, 1822-1828.	0.4	80
42	Freeze-all versus fresh blastocyst transfer strategy during in vitro fertilisation in women with regular menstrual cycles: multicentre randomised controlled trial. <i>BMJ, The</i> , 2020, 370, m2519.	3.0	80
43	The type of GnRH analogue used during controlled ovarian stimulation influences early embryo developmental kinetics: a time-lapse study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 168, 167-172.	0.5	79
44	Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. <i>Reproductive BioMedicine Online</i> , 2018, 37, 641-647.	1.1	78
45	Follicle Size on Day of Trigger Most Likely to Yield a Mature Oocyte. <i>Frontiers in Endocrinology</i> , 2018, 9, 193.	1.5	78
46	Malformation rate and sex ratio in 412 children conceived with epididymal or testicular sperm. <i>Human Reproduction</i> , 2007, 22, 1080-1085.	0.4	74
47	Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. <i>Journal of Assisted Reproduction and Genetics</i> , 2012, 29, 249-253.	1.2	74
48	Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone+gonadotropin-releasing hormone antagonist in vitro fertilization cycles. <i>Fertility and Sterility</i> , 2013, 100, 742-747.e1.	0.5	74
49	Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 200-207.	1.1	73
50	Pain relief during oocyte retrieval with a new short duration electro-acupuncture technique—an alternative to conventional analgesic methods. <i>Human Reproduction</i> , 2004, 19, 1367-1372.	0.4	72
51	The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. <i>Frontiers in Endocrinology</i> , 2019, 10, 814.	1.5	69
52	Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. <i>Human Reproduction</i> , 2011, 26, 2045-2053.	0.4	67
53	Individualized controlled ovarian stimulation in expected poor-responders: an update. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 20.	1.4	66
54	Day 3 versus day 5 embryo transfer: a prospective randomized study. <i>Reproductive BioMedicine Online</i> , 2003, 7, 98-104.	1.1	65

#	ARTICLE	IF	CITATIONS
55	New algorithm for OHSS prevention. <i>Reproductive Biology and Endocrinology</i> , 2011, 9, 147.	1.4	63
56	A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology. <i>Reproductive Biology and Endocrinology</i> , 2013, 11, 51.	1.4	63
57	Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. <i>Panminerva Medica</i> , 2019, 61, 3-10.	0.2	62
58	The Future of Cryopreservation in Assisted Reproductive Technologies. <i>Frontiers in Endocrinology</i> , 2020, 11, 67.	1.5	62
59	Luteal phase supplementation after Gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. <i>Fertility and Sterility</i> , 2015, 103, 879-885.	0.5	61
60	Dose of recombinant FSH and oestradiol concentration on day of HCG affect embryo development kinetics. <i>Reproductive BioMedicine Online</i> , 2012, 25, 382-389.	1.1	59
61	Recombinant human albumin as protein source in culture media used for IVF: a prospective randomized study. <i>Reproductive BioMedicine Online</i> , 2002, 4, 233-236.	1.1	58
62	GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles: A Systematic PRISMA Review and Meta-analysis. <i>Frontiers in Endocrinology</i> , 2017, 8, 116.	1.5	56
63	A strategy for treatment of couples with unexplained infertility who failed to conceive after intrauterine insemination. <i>Reproductive BioMedicine Online</i> , 2004, 8, 584-589.	1.1	55
64	GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. <i>Human Reproduction</i> , 2011, 26, 2874-2877.	0.4	54
65	Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols. <i>Reproductive Biology and Endocrinology</i> , 2012, 10, 9.	1.4	54
66	The impact of luteal serum progesterone levels on live birth rates: a prospective study of 602 IVF/ICSI cycles. <i>Human Reproduction</i> , 2018, 33, 1506-1516.	0.4	54
67	The impact of male overweight on semen quality and outcome of assisted reproduction. <i>Asian Journal of Andrology</i> , 2014, 16, 749.	0.8	53
68	Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. <i>Human Reproduction</i> , 2017, 32, 544-555.	0.4	53
69	Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. <i>Human Reproduction</i> , 2007, 23, 427-434.	0.4	52
70	Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. <i>Fertility and Sterility</i> , 2016, 105, 356-363.	0.5	52
71	Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. <i>Reproductive BioMedicine Online</i> , 2009, 18, 9-14.	1.1	51
72	Psychological aspects of male fertility treatment. <i>Journal of Advanced Nursing</i> , 2013, 69, 1977-1986.	1.5	51

#	ARTICLE	IF	CITATIONS
73	A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. <i>Reproductive Biology and Endocrinology</i> , 2014, 12, 95.	1.4	51
74	Gonadotropin-releasing hormone agonist (GnRHa) trigger – State of the art. <i>Reproductive Biology</i> , 2017, 17, 1-8.	0.9	51
75	Identification of the High-Risk Patient for Ovarian Hyperstimulation Syndrome. <i>Seminars in Reproductive Medicine</i> , 2010, 28, 458-462.	0.5	49
76	Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. <i>Human Reproduction</i> , 2006, 21, 2126-2130.	0.4	48
77	Prevalence, incidence, and autoimmune comorbidities of celiac disease: a nation-wide, population-based study in Denmark from 1977 to 2016. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 83-91.	0.8	48
78	Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. <i>Fertility and Sterility</i> , 2011, 95, 2034-2038.	0.5	47
79	Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger. <i>Fertility and Sterility</i> , 2013, 100, 994-1001.e2.	0.5	47
80	Increasing vaginal progesterone gel supplementation after frozen-thawed embryo transfer significantly increases the delivery rate. <i>Reproductive BioMedicine Online</i> , 2013, 26, 133-137.	1.1	47
81	Preparation of the Endometrium for Frozen Embryo Transfer: A Systematic Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 688237.	1.5	47
82	GnRHa trigger for final oocyte maturation: is HCG trigger history?. <i>Reproductive BioMedicine Online</i> , 2014, 29, 274-280.	1.1	45
83	Management Strategies for POSEIDON Groups 3 and 4. <i>Frontiers in Endocrinology</i> , 2019, 10, 614.	1.5	43
84	Reduced FSH and LH action: implications for medically assisted reproduction. <i>Human Reproduction</i> , 2021, 36, 1469-1480.	0.4	43
85	Reproductive outcome using a GnRH antagonist (cetorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. <i>Reproductive BioMedicine Online</i> , 2005, 11, 679-684.	1.1	41
86	Corifollitropin alfa followed by rFSH in a GnRH antagonist protocol for poor ovarian responder patients: an observational pilot study. <i>Fertility and Sterility</i> , 2013, 99, 422-426.	0.5	41
87	SARS-CoV-2 pandemic and repercussions for male infertility patients: A proposal for the individualized provision of andrological services. <i>Andrology</i> , 2021, 9, 10-18.	1.9	41
88	LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?. <i>Reproductive BioMedicine Online</i> , 2010, 21, 590-592.	1.1	40
89	Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	40
90	Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. <i>Human Reproduction</i> , 2015, 30, 2387-2395.	0.4	40

#	ARTICLE	IF	CITATIONS
91	Dual stimulation using corifollitropin alfa in 54 Bologna criteria poor ovarian responders â€“ a case series. <i>Reproductive BioMedicine Online</i> , 2019, 38, 677-682.	1.1	39
92	Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. <i>Reproductive BioMedicine Online</i> , 2011, 22, S67-S72.	1.1	38
93	Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. <i>Journal of Ovarian Research</i> , 2013, 6, 93.	1.3	38
94	Ovarian hyperstimulation syndrome in the 21st century. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 210-214.	0.9	38
95	Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection. <i>Frontiers in Endocrinology</i> , 2019, 10, 642.	1.5	38
96	Ovarian stimulation and assisted reproductive technology outcomes in women transplanted with cryopreserved ovarian tissue: a systematic review. <i>Fertility and Sterility</i> , 2019, 112, 908-921.	0.5	38
97	Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles. <i>Human Reproduction</i> , 2012, 27, 3259-3272.	0.4	37
98	Vaginal Microbiota and In Vitro Fertilization Outcomes: Development of a Simple Diagnostic Tool to Predict Patients at Risk of a Poor Reproductive Outcome. <i>Journal of Infectious Diseases</i> , 2019, 219, 1809-1817.	1.9	37
99	Fertility preservation and refreezing of transplanted ovarian tissueâ€”a potential new way of managing patients with low risk of malignant cell recurrence. <i>Fertility and Sterility</i> , 2017, 107, 1206-1213.	0.5	36
100	Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in <sc>IVF</sc> treatment. <i>Clinical Endocrinology</i> , 2018, 88, 920-927.	1.2	36
101	Characterization of the Vaginal DNA Virome in Health and Dysbiosis. <i>Viruses</i> , 2020, 12, 1143.	1.5	36
102	â€“Luteal coastingâ€” after GnRH agonist trigger â€“ individualized, HCG-based, progesterone-free luteal support in â€“high respondersâ€”: a case series. <i>Reproductive BioMedicine Online</i> , 2015, 31, 747-751.	1.1	35
103	Aromatase inhibitors in stimulated IVF cycles. <i>Reproductive Biology and Endocrinology</i> , 2011, 9, 85.	1.4	34
104	Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. <i>Human Reproduction</i> , 2017, 32, 2225-2233.	0.4	34
105	Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2110.	1.8	34
106	Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer. <i>Frontiers in Endocrinology</i> , 2019, 10, 639.	1.5	33
107	The early luteal hormonal profile in IVF patients triggered with hCG. <i>Human Reproduction</i> , 2020, 35, 157-166.	0.4	33
108	A prospective study, using sibling oocytes, examining the effect of 30 seconds versus 90 minutes gamete co-incubation in IVF. <i>Human Reproduction</i> , 2006, 21, 518-523.	0.4	32

#	ARTICLE	IF	CITATIONS
109	Daytime Variation in Serum Progesterone During the Mid-Luteal Phase in Women Undergoing In Vitro Fertilization Treatment. <i>Frontiers in Endocrinology</i> , 2018, 9, 92.	1.5	32
110	Therapeutic endometrial scratching and implantation after in vitro fertilization: a multicenter randomized controlled trial. <i>Fertility and Sterility</i> , 2019, 112, 1015-1021.	0.5	32
111	Spermatozoa DNA damage measured by sperm chromatin structure assay (SCSA) and birth characteristics in children conceived by IVF and ICSI. <i>Journal of Developmental and Physical Disabilities</i> , 2012, 35, 485-490.	3.6	30
112	Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients. <i>Human Reproduction</i> , 2021, 36, 2157-2169.	0.4	30
113	Use of Acupuncture in Female Infertility and a Summary of Recent Acupuncture Studies Related to Embryo Transfer. <i>Acupuncture in Medicine</i> , 2006, 24, 157-163.	0.4	29
114	(Meta)analyze this: Systematic reviews might lose credibility. <i>Nature Medicine</i> , 2012, 18, 1321-1321.	15.2	29
115	Frozen embryo transfer can be performed in the cycle immediately following the freeze-all cycle. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 135-142.	1.2	27
116	Can combining vaginal and rectal progesterone achieve the optimum progesterone range required for implantation in the HRT-FET model?. <i>Reproductive BioMedicine Online</i> , 2020, 40, 805-811.	1.1	27
117	Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. <i>International Journal of Reproductive BioMedicine</i> , 2018, 16, 9-18.	0.5	27
118	Pain relief during oocyte retrieval " exploring the role of different frequencies of electro-acupuncture. <i>Reproductive BioMedicine Online</i> , 2006, 13, 120-125.	1.1	26
119	"Follicular HCG endometrium priming for IVF patients experiencing resisting thin endometrium. A proof of concept study" <i>Journal of Assisted Reproduction and Genetics</i> , 2013, 30, 1341-1345.	1.2	26
120	The Circadian Variation in Anti-Müllerian Hormone in Patients with Polycystic Ovary Syndrome Differs Significantly from Normally Ovulating Women. <i>PLoS ONE</i> , 2013, 8, e68223.	1.1	25
121	Testosterone for Poor Ovarian Responders: Lessons From Ovarian Physiology. <i>Reproductive Sciences</i> , 2018, 25, 980-982.	1.1	25
122	Does the time interval between anti-Müllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization " intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. <i>Fertility and Sterility</i> , 2013, 100, 438-444.	0.5	24
123	Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. <i>Fertility and Sterility</i> , 2012, 97, 529-530.	0.5	23
124	Growth Hormone and Reproduction: Lessons Learned From Animal Models and Clinical Trials. <i>Frontiers in Endocrinology</i> , 2019, 10, 404.	1.5	23
125	Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders. <i>Gynecological Endocrinology</i> , 2015, 31, 885-890.	0.7	21
126	Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles. <i>Journal of Assisted Reproduction and Genetics</i> , 2016, 33, 207-214.	1.2	21

#	ARTICLE	IF	CITATIONS
127	Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. <i>Human Reproduction</i> , 2019, 34, 942-948.	0.4	21
128	Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 91.	1.4	21
129	GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. <i>Human Reproduction</i> , 2013, 28, 2593-2594.	0.4	20
130	Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology – “The king is dead, long live the king!” <i>Fertility and Sterility</i> , 2014, 102, 339-341.	0.5	20
131	The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors. <i>Reproductive BioMedicine Online</i> , 2015, 30, 563-565.	1.1	20
132	Reproductive life in women with celiac disease; a nationwide, population-based matched cohort study. <i>Human Reproduction</i> , 2018, 33, 1538-1547.	0.4	20
133	Freeze-all strategy in IVF/ICSI cycles: an update on clinical utility. <i>Panminerva Medica</i> , 2019, 61, 52-57.	0.2	20
134	Subcutaneous luteal phase progesterone rescue rectifies ongoing pregnancy rates in hormone replacement therapy vitrified “warmed blastocyst transfer cycles. <i>Reproductive BioMedicine Online</i> , 2021, 43, 45-51.	1.1	20
135	The combined effect of lifestyle intervention and antioxidant therapy on sperm DNA fragmentation and seminal oxidative stress in IVF patients: a pilot study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, 131-156.	0.7	20
136	Future Perspectives of POSEIDON Stratification for Clinical Practice and Research. <i>Frontiers in Endocrinology</i> , 2019, 10, 439.	1.5	19
137	Reproductive outcomes after in vitro fertilization treatment in a cohort of Danish women transplanted with cryopreserved ovarian tissue. <i>Fertility and Sterility</i> , 2020, 114, 379-387.	0.5	19
138	Addition of intramuscular progesterone to vaginal progesterone in hormone replacement therapy in vitrified “warmed blastocyst transfer cycles. <i>Reproductive BioMedicine Online</i> , 2020, 40, 812-818.	1.1	19
139	The Association between Vaginal Dysbiosis and Reproductive Outcomes in Sub-Fertile Women Undergoing IVF-Treatment: A Systematic PRISMA Review and Meta-Analysis. <i>Pathogens</i> , 2021, 10, 295.	1.2	19
140	Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial. <i>Frontiers in Endocrinology</i> , 2017, 8, 124.	1.5	18
141	Advances in ovulation trigger strategies. <i>Panminerva Medica</i> , 2019, 61, 42-51.	0.2	18
142	How time to healthy singleton delivery could affect decision-making during infertility treatment: a Delphi consensus. <i>Reproductive BioMedicine Online</i> , 2019, 38, 118-130.	1.1	18
143	Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment. <i>Frontiers in Endocrinology</i> , 2020, 11, 537205.	1.5	18
144	Gonadotropin-releasing hormone agonist for ovulation trigger – OHSS prevention and use of modified luteal phase support for fresh embryo transfer. <i>Upsala Journal of Medical Sciences</i> , 2020, 125, 131-137.	0.4	18

#	ARTICLE	IF	CITATIONS
145	Polymorphisms in the protein C inhibitor gene in in vitro fertilization failure. <i>Fertility and Sterility</i> , 2010, 93, 277-279.	0.5	17
146	Segmented ART – The new era in ART?. <i>Reproductive Biology</i> , 2016, 16, 91-103.	0.9	17
147	Individualized FSH dosing improves safety and reduces iatrogenic poor response while maintaining live-birth rates. <i>Human Reproduction</i> , 2018, 33, 982-983.	0.4	17
148	Relationship between a uterine fibroid diagnosis and the risk of adverse obstetrical outcomes: a cohort study. <i>BMJ Open</i> , 2020, 10, e032104.	0.8	16
149	Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial. <i>Fertility and Sterility</i> , 2010, 94, 2902-2904.	0.5	15
150	Case of successful IVF treatment of an oligospermic male with 46,XX/46,XY chimerism. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1325-1328.	1.2	15
151	Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study. <i>International Journal of Reproductive BioMedicine</i> , 2018, 16, 9-18.	0.5	15
152	The LH surge and ovulation re-visited: a systematic review and meta-analysis and implications for true natural cycle frozen thawed embryo transfer. <i>Human Reproduction Update</i> , 2022, 28, 717-732.	5.2	15
153	GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient?. <i>Reproductive BioMedicine Online</i> , 2018, 36, 75-77.	1.1	14
154	Female infertility and assisted reproductive technology. <i>Panminerva Medica</i> , 2019, 61, 1-2.	0.2	14
155	Oocyte quantity, as well as oocyte quality, plays a significant role for the cumulative live birth rate of a POSEIDON criteria patient. <i>Human Reproduction</i> , 2019, 34, 2555-2557.	0.4	14
156	Large-for-gestational age is male-gender dependent in artificial frozen embryo transfers cycles: a cohort study of 1295 singleton live births. <i>Reproductive BioMedicine Online</i> , 2020, 40, 134-141.	1.1	14
157	Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines. <i>Frontiers in Endocrinology</i> , 2021, 12, 587051.	1.5	14
158	Motivational interviewing: a part of the weight loss program for overweight and obese women prior to fertility treatment. <i>Gynecological Endocrinology</i> , 2013, 29, 839-842.	0.7	13
159	Persistent Mullerian Duct Syndrome: a rare entity with a rare presentation in need of multidisciplinary management. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 1237-1243.	0.7	13
160	Predicting live birth for poor ovarian responders: the PROsPeR concept. <i>Reproductive BioMedicine Online</i> , 2018, 37, 43-52.	1.1	13
161	Hormonal stimulation of spermatogenesis: a new way to treat the infertile male with non-obstructive azoospermia?. <i>International Urology and Nephrology</i> , 2019, 51, 453-456.	0.6	13
162	The Luteal Phase after GnRHa Trigger-Understanding An Enigma. <i>International Journal of Fertility & Sterility</i> , 2014, 8, 227-34.	0.2	13

#	ARTICLE	IF	CITATIONS
163	To add or not to add LH: comments on a recent commentary. <i>Reproductive BioMedicine Online</i> , 2006, 12, 284-285.	1.1	12
164	The gonadotropin-releasing hormone antagonist protocol – the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2012, 91, 643-647.	1.3	12
165	Mitochondrial DNA, a new biomarker of embryonic implantation potential: fact or fiction?. <i>Fertility and Sterility</i> , 2018, 109, 61-62.	0.5	12
166	Poor definition of poor-ovarian response results in misleading clinical recommendations. <i>Human Reproduction</i> , 2018, 33, 979-980.	0.4	12
167	Should Cochrane reviews be performed during the development of new concepts?. <i>Human Reproduction</i> , 2012, 27, 6-8.	0.4	11
168	GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study. <i>Reproductive Biology</i> , 2017, 17, 105-110.	0.9	11
169	Self-Detection of the LH Surge in Urine After GnRH Agonist Trigger in IVF – How to Minimize Failure to Retrieve Oocytes. <i>Frontiers in Endocrinology</i> , 2020, 11, 221.	1.5	11
170	Serum progesterone levels on day of embryo transfer in frozen embryo transfer cycles – the truth lies in the detail. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 2045-2046.	1.2	11
171	Endometrial compaction does not predict the reproductive outcome after vitrified-warmed embryo transfer: a prospective cohort study. <i>Reproductive BioMedicine Online</i> , 2022, 45, 81-87.	1.1	11
172	Comparison of a “freeze-all” strategy including GnRH agonist trigger versus a “fresh transfer” strategy including hCG trigger in assisted reproductive technology (ART): a study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2017, 7, e016106.	0.8	10
173	Unrecognised coeliac disease among men and women undergoing fertility treatment: A screening study. <i>United European Gastroenterology Journal</i> , 2018, 6, 1477-1484.	1.6	10
174	Gonadotropin-releasing hormone agonist ovulation trigger – beyond OHSS prevention. <i>Uppsala Journal of Medical Sciences</i> , 2020, 125, 138-143.	0.4	10
175	Artificial cryopreserved embryo transfer cycle success depends on blastocyst developmental rate and progesterone timing. <i>Reproductive BioMedicine Online</i> , 2018, 36, 269-276.	1.1	9
176	The “Big Freeze”: freeze-all should not be used for everyone. <i>Human Reproduction</i> , 2018, 33, 1577-1578.	0.4	9
177	Mitochondria and reproduction: possibilities for testing and treatment. <i>Panminerva Medica</i> , 2019, 61, 82-96.	0.2	9
178	Increased body mass index associated with increased preterm delivery in frozen embryo transfers. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 377-383.	0.4	9
179	Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG. <i>Frontiers in Endocrinology</i> , 2020, 11, 137.	1.5	9
180	Research and business – the yin and yang in modern medicine. <i>Reproductive BioMedicine Online</i> , 2020, 40, 613-616.	1.1	8

#	ARTICLE	IF	CITATIONS
181	Embryotoxicity testing of IVF disposables: how do manufacturers test?. Human Reproduction, 2020, 35, 283-292.	0.4	8
182	Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Human Reproduction Update, 2006, 12, 325-326.	5.2	7
183	Efficacy and Safety of Pergoveris in Assisted Reproductive Technologyâ€”ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment. BMJ Open, 2015, 5, e008297.	0.8	7
184	Protein supplementation intake for bodybuilding and resistance training may impact sperm quality of subfertile men undergoing fertility treatment: a pilot study. Asian Journal of Andrology, 2019, 21, 208.	0.8	7
185	Non-transparent and insufficient descriptions of non-validated microbiome methods and related reproductive outcome results should be interpreted with caution. Human Reproduction, 2019, 34, 2083-2084.	0.4	7
186	Diagnostic Accuracy of a Point-of-Care Test for Celiac Disease Antibody Screening among Infertile Patients. Inflammatory Intestinal Diseases, 2019, 4, 123-130.	0.8	7
187	Pregnancy and birth after intracytoplasmic sperm injection with normal testicular spermatozoa in a patient with azoospermia and tail stump epididymal sperm. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 1220-1225.	0.7	6
188	Paraurethral Leiomyoma in a Postmenopausal Woman: First European Case. Case Reports in Obstetrics and Gynecology, 2015, 2015, 1-3.	0.2	6
189	Azoospermia and ring chromosome 9â€”a case report. Journal of Assisted Reproduction and Genetics, 2015, 32, 293-296.	1.2	6
190	Treatment of Abnormal Vaginal Microbiota before Frozen Embryo Transfer: Case-Report and Minireview to Discuss the Longitudinal Treatment Efficacy of Oral Clindamycin. Frontiers in Physiology, 2017, 8, 415.	1.3	6
191	Mid-Luteal 17-OH Progesterone Levels in 614 Women Undergoing IVF-Treatment and Fresh Embryo Transferâ€”Daytime Variation and Impact on Live Birth Rates. Frontiers in Endocrinology, 2018, 9, 690.	1.5	6
192	The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders. Reproductive BioMedicine Online, 2020, 40, 223-228.	1.1	6
193	The POSEIDON stratification - moving from poor ovarian response to low prognosis. Jornal Brasileiro De Reproducao Assistida, 2021, 25, 282-292.	0.3	6
194	Suboptimal response to GnRH agonist trigger: causes and practical management. Current Opinion in Obstetrics and Gynecology, 2021, 33, 213-217.	0.9	6
195	POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 85, 159-187.	1.4	6
196	Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles. Journal of Assisted Reproduction and Genetics, 2017, 34, 471-478.	1.2	5
197	Vaginal microbiota and IVF outcomes: poor diagnosis results in flawed conclusions. Reproductive BioMedicine Online, 2019, 39, 178.	1.1	5
198	Bureaucratic overheating is a parasite hampering modern clinical research â€” a viewpoint from the â€”belly of the beastâ€™. Reproductive BioMedicine Online, 2019, 38, 487-489.	1.1	5

#	ARTICLE	IF	CITATIONS
199	GnRHa for trigger and luteal phase support in natural cycle frozen embryo transfer – A proof of concept study. <i>Reproductive Biology</i> , 2020, 20, 282-287.	0.9	5
200	The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients. <i>Reproductive BioMedicine Online</i> , 2021, 42, 1108-1118.	1.1	5
201	Response: Intensive luteal phase support with oestradiol and progesterone after GnRH agonist triggering: does it help?. <i>Reproductive BioMedicine Online</i> , 2012, 24, 682-683.	1.1	4
202	Concurrent oocyte retrieval and hysteroscopy: a novel approach in assisted reproduction freeze-all cycles. <i>Reproductive BioMedicine Online</i> , 2016, 33, 206-213.	1.1	4
203	Spontaneous clinical pregnancy following GnRH agonist trigger for final oocyte maturation and freeze-all approach: a case report. <i>Reproductive BioMedicine Online</i> , 2016, 32, 233-236.	1.1	4
204	Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output: a randomized controlled study. <i>Reproductive BioMedicine Online</i> , 2017, 35, 232-238.	1.1	4
205	Separation and characterization of maternal cardiac and vascular sounds in the third trimester of pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 137, 253-259.	1.0	4
206	Testing of sperm DNA damage and clinical recommendations. <i>Translational Andrology and Urology</i> , 2017, 6, S607-S609.	0.6	4
207	45,X/46,XY Mosaicism and Normozoospermia in a Patient with Male Phenotype. <i>Case Reports in Medicine</i> , 2019, 2019, 1-5.	0.3	4
208	Effect of clindamycin and a live biotherapeutic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota: protocol for a double-blind, placebo-controlled multicentre trial. <i>BMJ Open</i> , 2020, 10, e035866.	0.8	4
209	SESSION 46: ENDOMETRIOSIS/ENDOMETRIUM: CLINICAL STRATEGIES, EVIDENCED OUTCOMES. <i>Human Reproduction</i> , 2012, 27, ii66-ii67.	0.4	4
210	Vitrified-warmed blastocyst transfer timing related to LH surge in true natural cycle and its impact on ongoing pregnancy rates. <i>Reproductive BioMedicine Online</i> , 2022, 45, 440-447.	1.1	4
211	Posters * Reproductive Endocrinology (i.e. PCOS, Menarche, Menopause etc.). <i>Human Reproduction</i> , 2010, 25, i285-i321.	0.4	3
212	Endometrial Stromal Nodule: A Rarity and a Pathological Challenge. <i>Case Reports in Obstetrics and Gynecology</i> , 2015, 2015, 1-4.	0.2	3
213	Male infertility and assisted reproductive technology. <i>Panminerva Medica</i> , 2019, 61, 101-103.	0.2	3
214	Effect of whey protein supplementation on sperm quality and fertility in male mice. <i>Food and Chemical Toxicology</i> , 2020, 141, 111366.	1.8	3
215	Live birth after intrauterine insemination: is there an upper cut-off for the number of motile spermatozoa inseminated?. <i>Reproductive BioMedicine Online</i> , 2021, 42, 117-124.	1.1	3
216	Role of the total progressive motile sperm count (TPMSC) in different infertility factors in IUI: a retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e040563.	0.8	3

#	ARTICLE	IF	CITATIONS
217	GnRH agonist supplementation in hormone replacement therapyâ€œfrozen embryo transfer cycles: a randomized controlled trial. <i>Reproductive BioMedicine Online</i> , 2022, 44, 261-270.	1.1	3
218	Recombinant gonadotropin therapy to improve spermatogenesis in nonobstructive azoospermic patients - A proof of concept study.. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2022, 48, .	0.7	3
219	Reply: GnRHa to trigger final oocyte maturation: a time to reconsider. <i>Human Reproduction</i> , 2010, 25, 807-808.	0.4	2
220	Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. <i>Human Reproduction Update</i> , 2012, 18, 229-230.	5.2	2
221	Low biomass microbiota in the upper genital tract of reproductive age women: fact or fiction?. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 41.	1.7	2
222	Reply: Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI. <i>Human Reproduction Open</i> , 2021, 2021, hoab006.	2.3	2
223	Ovulation before or after intrauterine insemination does not affect live birth rates: a retrospective cohort study of 6701 cycles. <i>Reproductive BioMedicine Online</i> , 2021, 42, 1015-1022.	1.1	2
224	FEMALE (IN)FERTILITY. <i>Human Reproduction</i> , 2012, 27, ii226-ii247.	0.4	2
225	IVF and the exogenous progesterone-free luteal phase. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 188-195.	0.9	2
226	BehÃ§et's Disease (A severe case from Greenland). <i>Journal of Laryngology and Otology</i> , 1986, 100, 367-370.	0.4	1
227	Reply: GnRH agonist (buserelin) or hCG for ovulation induction in gnRH antagonist IVF/ICSI cycles: a prospective randomized study. <i>Human Reproduction</i> , 2005, 20, 3260-3260.	0.4	1
228	Reply: Luteal support post GnRH agonist trigger: do not stop too soon. <i>Human Reproduction</i> , 2005, 20, 3257-3258.	0.4	1
229	Lutropin Alfa. <i>Drugs</i> , 2008, 68, 1541-1542.	4.9	1
230	Session 33: Psychology & Counselling 2. <i>Human Reproduction</i> , 2010, 25, i49-i52.	0.4	1
231	Prenatal diagnostics in TESA/PESA pregnancies in Denmark 1995-2007: a shift from invasive procedures to nuchal translucency examination. <i>Systems Biology in Reproductive Medicine</i> , 2011, 57, 256-260.	1.0	1
232	POSTER VIEWING SESSION - EARLY PREGNANCY. <i>Human Reproduction</i> , 2011, 26, i151-i160.	0.4	1
233	POSTER VIEWING SESSION - QUALITY AND SAFETY OF ART THERAPIES. <i>Human Reproduction</i> , 2011, 26, i272-i278.	0.4	1
234	Treatment of poor ovarian responders with corifollitropin alpha followed by rFSH in an antagonist protocol. an observational pilot study. <i>Fertility and Sterility</i> , 2012, 98, S176.	0.5	1

#	ARTICLE	IF	CITATIONS
235	Association between maternal vascular murmur and the small-for-gestational-age fetus with abnormal umbilical artery Doppler flow. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 139, 211-216.	1.0	1
236	Hot topics in female infertility: an afterword. <i>Panminerva Medica</i> , 2019, 61, 97-99.	0.2	1
237	Reply to "Pain relief using electro-acupuncture for oocyte retrieval". <i>Human Reproduction</i> , 2004, 19, 2966-2967.	0.4	0
238	Serum progesterone levels on the day of HCG administration after controlled ovarian stimulation, are directly correlated to serum lh levels, number of follicles > 10 mm and number of oocytes retrieved. <i>Fertility and Sterility</i> , 2009, 92, S223.	0.5	0
239	High late follicular phase serum progesterone levels do not have a negative impact on pregnancy outcome in patients undergoing controlled ovarian hyperstimulation (COH) for IVF: results of a large RCT. <i>Fertility and Sterility</i> , 2009, 92, S84-S85.	0.5	0
240	Posters * Early Pregnancy. <i>Human Reproduction</i> , 2010, 25, i161-i170.	0.4	0
241	Men in ICSI treatment - Psychological aspects of male infertility. <i>Journal of Men's Health</i> , 2010, 7, 300-300.	0.1	0
242	The type of gonadotropins used for controlled ovarian stimulation affects embryo developmental kinetics. <i>Fertility and Sterility</i> , 2011, 96, S255-S256.	0.5	0
243	Follicular HCG endometrium priming for IVF patients experiencing resisting thin endometrium. a proof of concept study. <i>Fertility and Sterility</i> , 2013, 100, S469.	0.5	0
244	The ESPART randomized controlled trial in poor ovarian responders aligned with the Bologna criteria: a post hoc subgroup analysis according to poor ovarian response inclusion criteria. <i>Fertility and Sterility</i> , 2016, 106, e191.	0.5	0
245	Clinical, obstetrical and perinatal outcomes of freeze-all cycles: systematic review and meta-analysis of randomized controlled trials. <i>Fertility and Sterility</i> , 2018, 110, e79-e80.	0.5	0
246	Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer. <i>Human Reproduction</i> , 2018, 33, 2314-2315.	0.4	0
247	Nonspecific Symptoms in a Rare Case of Urethral Adenocarcinoma in a 58-Year-Old Female. <i>Case Reports in Obstetrics and Gynecology</i> , 2018, 2018, 1-3.	0.2	0
248	Hot topics in male infertility: an afterword. <i>Panminerva Medica</i> , 2019, 61, 196-199.	0.2	0
249	Blastocyst ploidy is not related to the number of embryos generated nor to the type of ovarian stimulation. <i>Fertility and Sterility</i> , 2019, 112, e134.	0.5	0
250	Editorial: POSEIDON's Stratification of "Low Prognosis" Patients in ART: The WHY, the WHAT, and the HOW. <i>Frontiers in Endocrinology</i> , 2021, 12, 719647.	1.5	0
251	SESSION 05: EARLY PREGNANCY. <i>Human Reproduction</i> , 2012, 27, ii9-ii11.	0.4	0
252	SESSION 37: APPROACHES FOR AVOIDING OHSS. <i>Human Reproduction</i> , 2012, 27, ii55-ii55.	0.4	0

#	ARTICLE	IF	CITATIONS
253	REPLY BY THE AUTHORS: Re: Persistent Mullerian Duct Syndrome: a rare entity with a rare presentation in need of multidisciplinary management. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1005-1006.	0.7	0
254	The Microbiome Environment Influences IVF Results. , 2021, , 268-270.		0
255	Immediate versus postponed single blastocyst transfer in modified natural cycle frozen embryo transfer (mNC-FET): a study protocol for a multicentre randomised controlled trial. BMJ Open, 2021, 11, e053234.	0.8	0
256	P-406â€fOngoing pregnancy rates (OPRs) after warmed blastocyst transfer (WBT) in a true-natural cycle (t-NC) are similar using six different luteinizing hormone (LH) surge criteria. Human Reproduction, 2022, 37, .	0.4	0
257	P-679â€fComparison of hormone replacement treatment (HRT) and true-natural cycle (t-NC) protocols for endometrial priming: An analysis of 1,815 warmed blastocyst transfer cycles. Human Reproduction, 2022, 37, .	0.4	0
258	P-298â€fThe live birth rate of the endometriosis patient is significantly increased by high luteal phase serum progesterone in HRT-FET cycles - A cohort study. Human Reproduction, 2022, 37, .	0.4	0